ArticleInternational journal of spine surgery2026
Five-Year Outcomes of Transforaminal Endoscopic Lumbar Decompression for Lateral Recess Stenosis in Patients With Chronic Systemic Disease.
Article in International journal of spine surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransforaminal endoscopic lumbar decompression (TELD) has emerged as a minimally invasive treatment for lumbar lateral recess stenosis (LRS). However, long-term outcomes in patients with chronic systemic disease remain insufficiently characterized.
objectiveTo evaluate the clinical outcomes and safety of TELD in patients with chronic systemic disease undergoing surgery for symptomatic single-level lumbar LRS.
methodsThis retrospective observational study included patients with chronic systemic disease who underwent TELD with reamed foraminoplasty for symptomatic single-level lumbar LRS at a single tertiary spine center between January 2016 and March 2021. Clinical outcomes were assessed using visual analog scale (VAS) scores for leg and back pain, the Oswestry Disability Index, and modified MacNab criteria. Follow-up was conducted for 60 months. Early complications (≤30 days) and reoperations were recorded.
resultsA total of 67 patients (mean age 59 ± 11.4 years) were available for 5-year follow-up. Mean operative time was 41 ± 8 minutes. VAS leg pain improved from 7.8 ± 1.3 preoperatively to 1.8 ± 0.8 at 60 months (
conclusionsTELD resulted in significant and durable improvements in pain and functional disability over a 5-year follow-up period in patients with chronic systemic disease. These findings support TELD as a safe and effective minimally invasive treatment option for carefully selected patients with chronic systemic disease and lumbar LRS. CLINICAL RELEVANCE: This study highlights TELD as a viable minimally invasive treatment option for patients with chronic systemic disease, offering durable symptom relief in a carefully selected cohort. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.